Copyright
©The Author(s) 2023.
World J Gastroenterol. May 7, 2023; 29(17): 2642-2656
Published online May 7, 2023. doi: 10.3748/wjg.v29.i17.2642
Published online May 7, 2023. doi: 10.3748/wjg.v29.i17.2642
Figure 4 Drug sensitivity test.
A: DPC-X1 is sensitive to oxaliplatin; IC50 = 13.26 μmol/L; B: DPC-X1 is sensitive to paclitaxel; IC50 = 0.014 μmol/L; C: DPC-X1 is resistant to fluorouracil; IC50 = 144.9 µmol/L; D: DPC-X1 is resistant to gemcitabine; IC50 > 600 μmol/L. IC50: Half maximal inhibitory concentration; TDC: Test drug concentrations.
- Citation: Xu H, Chai CP, Miao X, Tang H, Hu JJ, Zhang H, Zhou WC. Establishment and characterization of a new human ampullary carcinoma cell line, DPC-X1. World J Gastroenterol 2023; 29(17): 2642-2656
- URL: https://www.wjgnet.com/1007-9327/full/v29/i17/2642.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i17.2642